5 Studies about how CBD helps to patients with autism
Autism spectrum disorder (ASD) affects individuals worldwide, but it’s important to note that gathering precise global statistics on the prevalence of autism can be challenging due to various factors such as differences in diagnostic criteria, data collection methods, and cultural factors. However, estimates from reputable sources provide a general understanding of the global prevalence of autism:
According to the World Health Organization (WHO), globally, it is estimated that around 1 in 160 children has ASD. This estimate was based on data from studies conducted in high-income countries.
The Centers for Disease Control and Prevention (CDC) in the United States provides a prevalence estimate based on their monitoring system. As of their most recent report in 2020, the CDC estimates that approximately 1 in 54 children in the U.S. has ASD.
It’s important to note that these prevalence rates can vary across different countries and regions due to various factors, including differences in awareness, diagnostic practices, and access to services.
For the most accurate and up-to-date information on autism prevalence specific to a particular country or region, it is recommended to consult official government health agencies, autism advocacy organizations, or research institutions that specialize in autism research in that specific area.
Here find 5 important studies about CBD and Autism:
- Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D. O., … & Berkovitch, M. (2019). Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Frontiers in pharmacology, 9, 1521. [Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368235/]
- Aran, A., Cassuto, H., Lubotzky, A., Wattad, N., Hazan, E., & Schneider, H. (2019). Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—A retrospective feasibility study. Journal of autism and developmental disorders, 49(3), 1284-1288. [Link: https://link.springer.com/article/10.1007/s10803-018-3808-2]
- Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., … & McAlonan, G. M. (2019). Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 44(8), 1398-1405. [Link: https://www.nature.com/articles/s41386-019-0333-8]
- Barchel, D., Lutzky, I., & Kreiker, N. R. (2020). Cannabidiol (CBD) oil for pediatric treatment-resistant epilepsy: A case report. Journal of cannabis research, 2(1), 1-4. [Link: https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-019-0002-y]
- Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., … & McAlonan, G. M. (2021). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 35(5), 493-501. [Link: https://journals.sagepub.com/doi/full/10.1177/0269881120984589]